Cyclobenzaprine
سیکلوبنزاپرین
🦴 Musculo-Skeletal SystemSkeletal muscle relaxant
Market / country: 🇺🇸 USA
Flexeril (US)
🧮 Dose calculator
Painful muscle spasm · Regimen source: FDA Cyclobenzaprine · Dosage and Administration
- • If needed 10 mg three times daily. Use beyond 2–3 weeks not recommended. FDA Cyclobenzaprine · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; with or within 14 days of an MAOI; acute recovery phase of MI; arrhythmias, heart block or conduction disturbances; heart failure; hyperthyroidism. FDA Cyclobenzaprine · Contraindications
- ⛔ Not established under 15 years. FDA Cyclobenzaprine · Pediatric Use
Formulations
- 5 mg tablet — tablet 🇺🇸 USA FDA Cyclobenzaprine · How Supplied
- 7.5 mg tablet — tablet 🇺🇸 USA FDA Cyclobenzaprine · How Supplied
- 10 mg tablet — tablet 🇺🇸 USA FDA Cyclobenzaprine · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Cyclobenzaprine · Pregnancy
“Pregnancy Category B: Reproduction studies have been performed in rats, mice and rabbits atdoses up to 20 times the human dose, and have revealed no evidence of impaired fertility or harm to the fetus due to cyclobenzaprine hydrochloride.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Cyclobenzaprine · Nursing Mothers
“Because cyclobenzaprine is closely related to the tricyclic antidepressants, some of which are known to be excreted in human milk, caution should be exercised when cyclobenzaprine hydrochloride is administered to a nursing woman.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Cyclobenzaprine · Pediatric Use
“Safety and effectiveness of cyclobenzaprine hydrochloride in pediatric patients below 15 years of age have not been established.”
- 👴 Older adultsNo data
The source for this drug has no section for this group.
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA213324
- DailyMed (FDA label)FDA Cyclobenzaprine
- MedlinePlus (NIH)CyclobenzaprineCyclobenzaprine Sublingual
- WHO ATC/DDDM03BX08
- Darooyab (Iran)Cyclobenzaprine
🇮🇷 Not found in Iran list Darooyab · G-2790/Cyclobenzaprine
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Cyclobenzaprine · How SuppliedFDA Cyclobenzaprine · Dosage and AdministrationFDA Cyclobenzaprine · ContraindicationsFDA Cyclobenzaprine · Pediatric UseFDA Cyclobenzaprine · PregnancyFDA Cyclobenzaprine · Nursing MothersFDA Cyclobenzaprine · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-2790/Cyclobenzaprine
- Clinical review⚠ Unverified